Free Trial

Adlai Nortye (ANL) Stock Price, News & Analysis

-1.53 (-12.72%)
(As of 05/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
17,703 shs
Average Volume
4,080 shs
Market Capitalization
$387.45 million
P/E Ratio
Dividend Yield
Price Target

Adlai Nortye MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
185.7% Upside
$30.00 Price Target
Short Interest
0.03% of Shares Sold Short
Dividend Strength
News Sentiment
0.09mentions of Adlai Nortye in the last 14 days
Based on 6 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.22 out of 5 stars

Medical Sector

764th out of 923 stocks

Pharmaceutical Preparations Industry

338th out of 405 stocks

ANL stock logo

About Adlai Nortye Stock (NASDAQ:ANL)

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

ANL Stock Price History

ANL Stock News Headlines

See More Headlines
Receive ANL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adlai Nortye and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Pretax Margin


Sales & Book Value

Annual Sales


Free Float
Market Cap
$387.45 million
Not Optionable
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Yang Lu (Age 43)
    CEO & Chairman
  • Ms. Wei Zhang (Age 32)
    Chief Financial Officer
  • Dr. Kaiyang Tang (Age 59)
    Senior VP & Global Head of Clinical Operations
  • Dr. Victoria Elizabeth Demby Ph.D. (Age 53)
    Senior VP & Global Head of Regulatory Affairs
  • Dr. Ngai Chiu Tse M.D. (Age 56)
    Ph.D., Head of Research & Development

ANL Stock Analysis - Frequently Asked Questions

Should I buy or sell Adlai Nortye stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adlai Nortye in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANL shares.
View ANL analyst ratings
or view top-rated stocks.

What is Adlai Nortye's stock price target for 2024?

1 brokerages have issued 12-month price objectives for Adlai Nortye's shares. Their ANL share price targets range from $30.00 to $30.00. On average, they anticipate the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 185.7% from the stock's current price.
View analysts price targets for ANL
or view top-rated stocks among Wall Street analysts.

How have ANL shares performed in 2024?

Adlai Nortye's stock was trading at $8.99 at the start of the year. Since then, ANL stock has increased by 16.8% and is now trading at $10.50.
View the best growth stocks for 2024 here

When did Adlai Nortye IPO?

Adlai Nortye (ANL) raised $58 million in an IPO on Friday, September 29th 2023. The company issued 2,500,000 shares at $23.00 per share.

When did Adlai Nortye's lock-up period expire?

Adlai Nortye's lock-up period expired on Wednesday, March 27th. Adlai Nortye had issued 2,500,000 shares in its IPO on September 29th. The total size of the offering was $57,500,000 based on an initial share price of $23.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

How do I buy shares of Adlai Nortye?

Shares of ANL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANL) was last updated on 5/26/2024 by Staff

From Our Partners